GlassScriptPhysician profile
Karah Freeman Smith
NPI 1285622746
$2,152.50
in general payments reported to CMS, 2019-2025
29 companies · $55.07 in 2025
The $55.07 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.51 · 2022: $544 · 2023: $747 · 2024: $790 · 2025: $55.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $345.81 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $341.62 | 2022-2024 | |
| Pfizer INC. | $273.67 | 2022-2024 | |
| Novo Nordisk INC | $229.01 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $120.15 | 2022-2025 | Freestyle Libre 3, Eterna |
| Amgen INC. | $99.97 | 2022-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $92.49 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.17 | 2022-2024 | Ofev, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $72.11 | 2022 | |
| Medtronic, INC. | $59.49 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Phathom Pharmaceuticals, INC. | $53.48 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $40.14 | 2022-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $36.55 | 2022-2024 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $29.91 | 2022-2024 | Farxiga |
| Astellas Pharma US INC | $25.42 | 2024 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.68 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2022 | |
| Bausch Health US, LLC | $18.71 | 2022 | |
| Averitas Pharma INC. | $18.71 | 2023 | Qutenza |
| Corcept Therapeutics | $17.80 | 2025 | Korlym |
| Eisai INC. | $17.18 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.00 | 2024 | Trulance, Xifaxan |
| Irhythm Technologies, INC. | $16.80 | 2023 | Zio Xt Patch |
| Axonics, INC. | $16.51 | 2021 | |
| Seqirus USA INC | $15.69 | 2022 | |
| Shield Therapeutics INC | $15.28 | 2022 | |
| Boston Scientific Corporation | $14.68 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $13.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.